We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Chemotherapy for biliary tract cancer: real-world experience in a single institute.
- Authors
Osamu Maeda; Tomoki Ebata; Tomoya Shimokata; Ayumu Matsuoka; Megumi Inada-Inoue; Sachi Morita; Yuko Takano; Hiroshi Urakawa; Yuki Miyai; Mihoko Sugishita; Ayako Mitsuma; Masahiko Ando; Takashi Mizuno; Masato Nagino; Yuichi Ando
- Abstract
The standard chemotherapy regimen for unresectable or recurrent biliary tract cancer is gemcitabine combined with cisplatin (GC). To evaluate the effectiveness and safety of chemotherapy in patients with unresectable or recurrent biliary tract cancer in the real world, we retrospectively analyzed the clinical courses of patients who underwent chemotherapy with GC from January 2015 to November 2019. Fortyeight patients underwent the GC regimen. One patient (2.1%) achieved a complete response, seven patients (14.6%) achieved a partial response, 26 patients (54.2) achieved stable disease, 11 patients (22.9%) achieved progressive disease, and 3 patients (6.3%) were not evaluable. The overall response rate was 16.7%. The median overall survival was 14.2 months (95% CI: 13.8--14.6), and the median progression-free survival was 7.7 months (95% CI: 4.2-11.2). Thirty-nine patients (81.3%) experienced grade 3 or higher severe adverse events as follows: 54.2% experienced neutropenia, 20.8% experienced anemia, 12.5% experienced thrombocytopenia and 20.8% experienced biliary tract infection. As a second-line chemotherapy, S-1 was used in seventeen patients, and stable disease was achieved in three patients (17.6%). The GC regimen for biliary tract cancer is effective and safe for unresectable or recurrent biliary tract cancer in routine clinical practice.
- Subjects
BILIARY tract cancer; CANCER chemotherapy; CISPLATIN; PROGRESSION-free survival; ADVERSE health care events
- Publication
Nagoya Journal of Medical Science, 2020, Vol 82, Issue 4, p725
- ISSN
0027-7622
- Publication type
Article
- DOI
10.18999/nagjms.82.4.725